ERYTHROCYTE SODIUM-TRANSPORT IN MALIGNANT HYPERTENSION

被引:1
|
作者
HERLITZ, H
HILME, E
JONSSON, O
GUDBRANDSSON, T
HANSSON, L
机构
[1] SAHLGRENS UNIV HOSP,DEPT UROL,S-41345 GOTHENBURG,SWEDEN
[2] GOTHENBURG UNIV,OSTRA HOSP,DEPT MED,S-41685 GOTHENBURG,SWEDEN
关键词
antihypertensive treatment; cellular sodium transport; erythrocytes; malignant hypertension;
D O I
10.1111/j.1365-2796.1990.tb00206.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Abstract. Twenty‐three patients with treated malignant hypertension (MH), 23 patients with treated non‐malignant hypertension (NMH) and 46 normotensive control subjects were investigated with regard to intraerythrocyte sodium (Na) and potassium (K) levels, as well as transmembrane fluxes of sodium (Na‐influx and Na‐efflux rate constant). Intraerythrocyte Na and K concentrations were determined by flame photometry. The Na‐influx and Na‐efflux rate constant were calculated from uptake values for 22Na in vitro. In NMH the Na‐influx and Na‐efflux rate constant were significantly higher while intraerythrocyte Na and K levels did not differ from the controls. Patients with MH tended to have an elevated intraerythrocyte Na concentration, but an unchanged Na‐influx and Na‐efflux rate constant relative to controls. The increased rate of erythrocyte membrane transport of Na in treated NMH could be due to a stimulatory effect of antihypertensive treatment on cellular Na transport. Patients with treated MH do not show this effect and, in addition, tend to have an elevated intraerythrocyte Na concentration, which is compatible with the existence of a more pronounced abnormality of cellular ion transport in MH. 1990 Blackwell Publishing Ltd
引用
收藏
页码:133 / 137
页数:5
相关论文
共 50 条
  • [11] THE CHARACTERISTICS OF ERYTHROCYTE NA plus TRANSPORT-SYSTEMS IN NORMAL-PREGNANCY AND PREGNANCY-INDUCED HYPERTENSION
    MIYAMOTO, S
    MAKINO, N
    SHIMOKAWA, H
    AKAZAWA, K
    WAKE, N
    NAKANO, H
    JOURNAL OF HYPERTENSION, 1992, 10 (04) : 367 - 372
  • [12] Echocardiographic changes in patients with malignant phase hypertension: The West Birmingham Malignant Hypertension Register
    S Nadar
    D G Beevers
    G Y H Lip
    Journal of Human Hypertension, 2005, 19 : 69 - 75
  • [13] Echocardiographic changes in patients with malignant phase hypertension: The west Birmingham Malignant Hypertension Register
    Nadar, S
    Beevers, DG
    Lip, GYH
    JOURNAL OF HUMAN HYPERTENSION, 2005, 19 (01) : 69 - 75
  • [14] Pharmacological management of malignant hypertension
    Lewek, Joanna
    Bielecka-Dabrowa, Agata
    Maciejewski, Marek
    Banach, Maciej
    EXPERT OPINION ON PHARMACOTHERAPY, 2020, 21 (10) : 1189 - 1192
  • [15] Malignant hypertension:: Ocular manifestations
    Munoz, Silvia
    Martin, Nieves
    Arruga, Jorge
    THESCIENTIFICWORLDJOURNAL, 2006, 6 : 122 - 124
  • [16] Malignant Hypertension with Thrombotic Microangiopathy
    Mitaka, Hayato
    Yamada, Yuji
    Hamada, Osamu
    Kosaka, Shintaro
    Fujiwara, Naoki
    Miyakawa, Yoshitaka
    INTERNAL MEDICINE, 2016, 55 (16) : 2277 - 2280
  • [17] ATPASE ERYTHROCYTE TRANSPORT SYSTEMS IN HUMAN BLOOD
    Fedorova, E. Yu
    Nalobina, A. N.
    Sizov, A. E.
    HUMAN SPORT MEDICINE, 2019, 19 : 61 - 67
  • [18] Oxidative stress in malignant and non-malignant phase hypertension
    Lip G.Y.H.
    Edmunds E.
    Nuttall S.L.
    Landray M.J.
    Blann A.D.
    Beevers D.G.
    Journal of Human Hypertension, 2002, 16 (5) : 333 - 336
  • [19] Predictors of 5-year outcomes in malignant phase hypertension: the West Birmingham Malignant Hypertension Registry
    Shantsila, Alena
    Shantsila, Eduard
    Beevers, D. Gareth
    Lip, Gregory Y. H.
    JOURNAL OF HYPERTENSION, 2017, 35 (11) : 2310 - 2314
  • [20] Oxidative stress in malignant and non-malignant phase hypertension
    Lip, GYH
    Edmunds, E
    Nuttall, SL
    Landray, MJ
    Blann, AD
    Beevers, DG
    JOURNAL OF HUMAN HYPERTENSION, 2002, 16 (05) : 333 - 336